Waltham, MA-based biotech firm Alkermes (NASDAQ:[[ticker:ALKS]]) said today that the FDA has approved its extended-release formulation of naltrexone (Vivitrol) for preventing the relapse of opioid drug dependence. The firm’s drug, which is injected once per month, was initially approved for alcohol dependence in 2006. The company will discuss the new approval of the drug during a conference call scheduled for 8 am ET on Wednesday.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
